Hikma Pharmaceuticals PLC (HIK)
London Exchange · UK · prices in GBX · close of 20 Oct 2026
Key indicators
| Last close | GBX 1,652.00 |
|---|---|
| 52-week range | 1,134.72 – 1,782.86 |
| Return, 1 month / 3 months | +2.5% / +7.1% |
| Return, 1 year / 3 years | −3.1% / −5.9% |
| Trend | Uptrend |
| RSI (14) | 57 |
| Volatility (1 year) | 35.8% |
| Worst drawdown (1 year) | -35.2% |
| Average daily value traded | 1,186.65M GBX |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Hikma Pharmaceuticals is a pharmaceutical company that develops, manufactures and markets generic and branded medicines. Its products include injectable medicines, oral tablets and capsules, and other prescription treatments supplied to hospitals, clinics and pharmacies. The company operates manufacturing sites and sales operations across the Middle East and North Africa, the United States and Europe, and it is headquartered in London. It serves healthcare providers and patients through a portfolio of generic and licensed medicines.
On this site Hikma Pharmaceuticals PLC appears as a stock on the London Exchange (UK), code HIK, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Hikma Pharmaceuticals PLC (HIK) trades on the London Exchange in UK. It last closed at GBX 1,652.00 on 20 October 2026.
Its price-based Market X-Ray is 64 out of 100 (a fair price profile), ranking 979 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 3.1% and over the last three months it rose 7.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 78 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 12.4% | ||
| From 52-week high | -6.0% | ||
| Momentum | 65 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 7.1% | ||
| 6-month return | 27.1% | ||
| 12-month return, skipping the last month | -5.5% | ||
| Stability (higher is calmer) | 44 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 35.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -35.2% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 1,186.65M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 30 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.2% |
|---|---|
| 1 month | +2.5% |
| 3 months | +7.1% |
| 6 months | +27.1% |
| 1 year | −3.1% |
| 3 years | −5.9% |
| 5 years | −21.4% |
Signals
| 50-day / 200-day average | 1,608.54 / 1,469.58 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 42.12 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 Aug 2026 | GBP 0.2909 |
| 19 Mar 2026 | GBP 0.3529 |
| 14 Aug 2025 | GBP 0.2701 |
| 20 Mar 2025 | GBP 0.3721 |
| 15 Aug 2024 | GBP 0.2427 |
| 21 Mar 2024 | GBP 0.3714 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.